The STREAMLINED Study: trAML, AML-MRC, CMML and MDS in England
Research type
Research Study
Full title
The STREAMLINED Study: Scrutinizing the treatment pathways, outcomes and healthcare resource use of trAML, AML-MRC, CMML and MDS in England
IRAS ID
273466
Contact name
Adrian Paul Rabe
Contact email
Sponsor organisation
Health iQ
Duration of Study in the UK
1 years, months, days
Research summary
Therapy-related acute myeloid leukaemia (trAML), acute myeloid leukaemia with myelodysplastic changes (AML-MRC), chronic myelomonocytic leukaemia (CMML) and myelodysplasia (MDS) are abnormalities involving specific types of white blood cells with potentially a common process of formation. Normal white blood cells function to protect the body as part of the immune system. In trAML, AML-MRC, CMML and MDS, these cells have mutated and may invade and harm different parts of the body. Being a very debilitating disease, it is important to understand how much resources they use up in the national health service, as well as the various treatments they undergo, and how those treatments impact their survival. This study aims to use anonymized and pseudonymized data from Public Health England to construct a group of patients with trAML, AML-MRC, CMML and MDS. Using the same dataset linked to secondary care and to the cancer treatment dataset, the study would determine healthcare resource use and treatment pathways, as well as clinical outcomes. The span of time covered would be from 2006 to the latest available data when it would be requested. Once completed, this study would hopefully inform health policy to reduce healthcare resources and reconfigure services to provide better treatment pathways for patients.
REC name
London - City & East Research Ethics Committee
REC reference
20/LO/0145
Date of REC Opinion
22 Jan 2020
REC opinion
Favourable Opinion